GONUTS has been updated to MW1.31 Most things seem to be working but be sure to report problems.
PMID:25294810
Citation |
Kazyken, D, Kaz, Y, Kiyan, V, Zhylkibayev, AA, Chen, CH, Agarwal, NK and Sarbassov, dos D (2014) The nuclear import of ribosomal proteins is regulated by mTOR. Oncotarget 5:9577-93 |
---|---|
Abstract |
Mechanistic target of rapamycin (mTOR) is a central component of the essential signaling pathway that regulates cell growth and proliferation by controlling anabolic processes in cells. mTOR exists in two distinct mTOR complexes known as mTORC1 and mTORC2 that reside mostly in cytoplasm. In our study, the biochemical characterization of mTOR led to discovery of its novel localization on nuclear envelope where it associates with a critical regulator of nuclear import Ran Binding Protein 2 (RanBP2). We show that association of mTOR with RanBP2 is dependent on the mTOR kinase activity that regulates the nuclear import of ribosomal proteins. The mTOR kinase inhibitors within thirty minutes caused a substantial decrease of ribosomal proteins in the nuclear but not cytoplasmic fraction. Detection of a nuclear accumulation of the GFP-tagged ribosomal protein rpL7a also indicated its dependence on the mTOR kinase activity. The nuclear abundance of ribosomal proteins was not affected by inhibition of mTOR Complex 1 (mTORC1) by rapamycin or deficiency of mTORC2, suggesting a distinctive role of the nuclear envelope mTOR complex in the nuclear import. Thus, we identified that mTOR in association with RanBP2 mediates the active nuclear import of ribosomal proteins. |
Links |
PubMed PMC4259421 Online version:10.18632/oncotarget.2473 |
Keywords |
Active Transport, Cell Nucleus; Cell Line, Tumor; Cell Nucleus/metabolism; HEK293 Cells; HeLa Cells; Humans; Molecular Chaperones/metabolism; Multiprotein Complexes/antagonists & inhibitors; Multiprotein Complexes/deficiency; Multiprotein Complexes/metabolism; Neoplasms/enzymology; Neoplasms/metabolism; Nuclear Pore Complex Proteins/metabolism; Ribosomal Proteins/metabolism; Sirolimus/pharmacology; TOR Serine-Threonine Kinases/antagonists & inhibitors; TOR Serine-Threonine Kinases/deficiency; TOR Serine-Threonine Kinases/metabolism |
Significance
Annotations
Gene product | Qualifier | GO Term | Evidence Code | with/from | Aspect | Extension | Notes | Status |
---|---|---|---|---|---|---|---|---|
GO:0005635: nuclear envelope |
ECO:0000314: |
C |
Figure 2A shows immunostaining of mTOR in the nuclear envelope. |
complete | ||||
GO:0005635: nuclear envelope |
ECO:0000314: |
C |
Figure 2A shows immunostaining of mTOR in the nuclear envelope. |
complete | ||||
GO:0005635: nuclear envelope |
ECO:0000314: |
C |
Figure 2B shows immunostaining of RanBP2 in the nuclear envelope. |
complete | ||||
GO:0005730: nucleolus |
ECO:0000314: |
C |
Figure 4(C1) shows accumulation of GFP-RPL7a in nucleolus of control cells. |
complete | ||||
GO:0005635: nuclear envelope |
ECO:0000314: |
C |
Figure 2B shows immunostaining of RanBP2 in the nuclear envelope. |
complete | ||||
GO:0005730: nucleolus |
ECO:0000314: |
C |
Figure 4(C1) shows accumulation of GFP-RPL7a in nucleolus of control cells. |
complete | ||||
Notes
See also
References
See Help:References for how to manage references in GONUTS.